Home
/
Denali Therapeutics Inc.
/
Financials
/
Quarterly
Denali Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Denali Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2024
Mar 31, 2024
$0
May 7, 2024
Q3
2023
Sep 30, 2023
$1.27M
Nov 7, 2023
Q2
2023
Jun 30, 2023
$294.12M
Aug 8, 2023
Q1
2024
Mar 31, 2023
$35.14M
May 7, 2024
Q3
2023
Sep 30, 2022
$3.56M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$52.48M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$42.14M
May 8, 2023
Q3
2022
Sep 30, 2021
$5.29M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$22.94M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$7.92M
May 5, 2022
Q3
2021
Sep 30, 2020
$9.39M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$5.85M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$3.60M
May 5, 2021
Q3
2020
Sep 30, 2019
$13.60M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$4.20M
Aug 7, 2020
Q1
2020
Mar 31, 2019
$4.21M
May 7, 2020
Q1
2018
Mar 31, 2018
$641.0K
May 11, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$0
Nov 6, 2024
Q2
2024
Jun 30, 2024
$0
Aug 1, 2024
Q1
2024
Mar 31, 2024
$0
May 7, 2024
Q3
2024
Sep 30, 2023
$1.27M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$294.12M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$35.14M
May 7, 2024
Q3
2023
Sep 30, 2022
$184.0K
Nov 7, 2023
Q2
2023
Jun 30, 2022
$52.48M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$42.14M
May 8, 2023
Q3
2022
Sep 30, 2021
$5.29M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$22.94M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$7.92M
May 5, 2022
Q3
2021
Sep 30, 2020
$9.39M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$5.81M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$3.55M
May 5, 2021
Q3
2020
Sep 30, 2019
$13.51M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$4.10M
Aug 7, 2020
Q1
2020
Mar 31, 2019
$4.11M
May 7, 2020
Q3
2019
Sep 30, 2018
$1.20M
Nov 6, 2019
Q2
2019
Jun 30, 2018
$1.65M
Aug 6, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($126.90M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($124.12M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($132.97M)
May 6, 2025
Q3
2025
Sep 30, 2024
($107.19M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($99.03M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($101.80M)
May 6, 2025
Q3
2024
Sep 30, 2023
($99.35M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
$183.38M
Aug 1, 2024
Q1
2024
Mar 31, 2023
($109.78M)
May 7, 2024
Q3
2023
Sep 30, 2022
($103.30M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($58.79M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($65.22M)
May 8, 2023
Q3
2022
Sep 30, 2021
($84.59M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($60.69M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($70.04M)
May 5, 2022
Q3
2021
Sep 30, 2020
($58.23M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($58.76M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($56.76M)
May 5, 2021
Q3
2020
Sep 30, 2019
($46.26M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($58.34M)
Aug 7, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($137.43M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($134.96M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($145.58M)
May 6, 2025
Q3
2025
Sep 30, 2024
($123.19M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($116.59M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($117.72M)
May 6, 2025
Q3
2024
Sep 30, 2023
($113.80M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
$170.48M
Aug 1, 2024
Q1
2024
Mar 31, 2023
($120.82M)
May 7, 2024
Q3
2023
Sep 30, 2022
($107.49M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($61.42M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($66.50M)
May 8, 2023
Q3
2022
Sep 30, 2021
($85.59M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($61.82M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($71.22M)
May 5, 2022
Q3
2021
Sep 30, 2020
($60.12M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($61.28M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($59.97M)
May 5, 2021
Q3
2020
Sep 30, 2019
($50.16M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($62.76M)
Aug 7, 2020